Parker Institute for Cancer Immunotherapy shared a post on LinkedIn:
“We are thrilled to announce that Mark Veich has joined the Parker Institute for Cancer Immunotherapy as Chief Organizational Advancement Officer.
Mark joins us from Deerfield Management, where he led nonprofit initiatives and served as CEO of Advancium Health Network. He also co-founded CobiCure Therapeutics, and previously served as Vice Provost for External Affairs at Weill Cornell Medicine and as Managing Director at Michigan Medicine.
A mission-driven leader and expert in mobilizing philanthropic and venture capital, Mark will guide PICI’s fundraising strategy and help drive strategic growth as we enter our 10th year. His leadership will expand our research and venture portfolios and accelerate our mission to develop and deliver breakthrough cancer therapies.
Please join us in welcoming Mark to PICI!
Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared this post, adding:
“Thrilled to have Mark Veich join our ranks as we develop and increase access to breakthrough cancer therapies. He’s practically one of the family already, and shares our vision to convert all cancers into curable diseases. Let’s GO!”
More posts about Parker Institute for Cancer Immunotherapy.